The moment arrives without warning. A chewed bottle on the floor. A litter of treats consumed in the thirty seconds you turned your back. The arithmetic of how many milligrams per kilogram your dog or cat just ingested running through your head while you search for an answer that the internet, characteristically, makes more frightening than the pharmacology warrants. The question you are actually asking is not whether CBD is dangerous in the abstract. It is whether what just happened to your animal is dangerous in the specific, and what you are supposed to do about it right now.

Six peer-reviewed investigations and one Merck Veterinary Manual clinical reference form the evidentiary foundation of this article. Their findings are presented as the authors reported them. The answer they collectively provide is more reassuring than most pet owners expect, with one critical qualification that this article will state plainly and repeat as many times as the data requires: the severe neurological signs that frighten owners after cannabis exposure are not caused by CBD. They are caused by THC. That distinction is not a technicality. It is the most clinically important fact in this entire article, and it is the fact that most consumer content about pet CBD either does not know or does not say.

The Safety Margin: What the Numbers Actually Show

Bookout and colleagues, publishing in Frontiers in Veterinary Science in 2024, administered CBD alone, CBD combined with CBG, and CBD combined with CBDA at 5 milligrams per kilogram of body weight per day for 90 consecutive days in 32 healthy beagles.^[1] All three treatment groups completed the study without serious adverse events. Transient alkaline phosphatase elevations were observed in the CBD group but returned to baseline over the course of the study and were not considered clinically significant by the investigators. The authors also analyzed pharmacovigilance data from the National Animal Supplement Council Adverse Event Reporting System covering 2010 through 2023. Across more than 1.077 billion total cannabinoid administrations to companion animals, the recorded adverse event rate was 2.19 per million administrations. The serious adverse event rate was 0.01 per million administrations.

Hammerding and Brutlag, writing in the Merck Veterinary Manual in 2026, confirmed the acute overdose thresholds that the controlled trial data implies.^[2] Acute oral overdoses up to 62 milligrams per kilogram produced only diarrhea in dogs. In cats, acute oral overdoses up to 80 milligrams per kilogram were well tolerated with no CBD-related clinical signs documented. Carrier-related transient salivation was noted in some cats, attributable to the vehicle rather than the cannabinoid. To place those numbers in context: a 10-kilogram dog would need to consume 620 milligrams of CBD in a single sitting to reach the threshold at which diarrhea was the documented outcome. A standard VetsGrade serving contains a fraction of that quantity.

What CBD Does at High Doses in Dogs

Pet Poison Helpline data analyzed by Hammerding and Brutlag, covering January 2018 through February 2023, provides the most granular picture available of what happens when dogs receive more CBD than intended.^[2] Of all CBD cases presenting to the helpline during that period, 45 percent of dogs remained clinically normal. Of those showing signs, lethargy was the most common presentation at 30 percent, followed by ataxia at 21 percent, vomiting at 15 percent, hypersalivation at 5 percent, and diarrhea at 3 percent. Urinary incontinence was documented in 6 to 7 percent of cases, as were trembling and hyperesthesia.

The authors make a finding that deserves to be read carefully: the neurological signs in that dataset, including ataxia, trembling, and hyperesthesia, are likely attributable to THC contamination, synthetic cannabinoids, or other adulterants in poorly manufactured products, not to CBD itself. This is not a speculative editorial position. It is the clinical conclusion of the investigators who reviewed the case data, and it is consistent with the mechanistic pharmacology of CBD, which does not produce the intoxicating neurological syndrome that THC produces through CB1 receptor agonism.

Ukai, McGrath, and Wakshlag, publishing in the Journal of the American Veterinary Medical Association in 2023, confirmed that ALP elevation documented in canine CBD studies does not accompany rises in GGT or bilirubin, the markers that would indicate genuine hepatic injury.^[4] The authors concluded that the ALP elevation is often innocuous, likely reflecting cytochrome P450 enzyme induction rather than hepatocellular damage, and recommended routine bloodwork monitoring for dogs receiving CBD chronically rather than discontinuation based on ALP elevation alone.

What CBD Does at High Doses in Cats

Coltherd and colleagues at the Waltham Petcare Science Institute, publishing in Frontiers in Veterinary Science in 2024, conducted a 26-week tolerance study in healthy cats receiving CBD at 4 milligrams per kilogram of body weight per day.^[3] All biochemistry, hematology, and urinalysis measures remained within reference ranges throughout the study period, with the exception of cholesterol, sodium-to-potassium ratio, mean platelet volume, and eosinophil count, none of which were considered clinically significant by the investigators. Three cats developed elevated ALT and were subsequently diagnosed with cholangitis, a common feline hepatic condition. Clinical opinion from the investigators was that CBD was unlikely to have caused the infection directly. One asymptomatic cat resolved within three weeks with return to normal ALT and AST values. The authors concluded that CBD is well tolerated by healthy cats at 4 milligrams per kilogram per day over 26 weeks.

Lyons and colleagues at the University of Saskatchewan, publishing in Frontiers in Veterinary Science in 2024, characterized the pharmacokinetics of a 1:20 THC:CBD cannabis herbal extract in 12 domestic shorthair cats at low dose (2mg CBD plus 0.1mg THC per kilogram) and high dose (5mg CBD plus 0.25mg THC per kilogram).^[5] The terminal elimination half-life reached a mean of 17.1 hours in the high dose group, with CBD detectable up to 48 hours post-dose. Two cats in the high dose group experienced moderate hypersalivation within 2 to 10 minutes of dosing, attributed to the oral administration process rather than systemic CBD effect. No vomiting, neurological abnormalities, sedation, or altered mentation was observed in any cat at either dose. The authors noted high intra-individual variability between cats in the same dose group, a finding with direct clinical implications: cats do not respond uniformly to the same dose, and conservative titration is warranted.

The pharmacokinetic distinction between dogs and cats is not incidental. Cats have lower hepatic glucuronidation capacity than dogs, meaning CBD clears more slowly, accumulates with repeated dosing, and reaches higher plasma concentrations at equivalent doses. This is not a reason to avoid CBD in cats. It is a reason to start at lower doses, titrate more slowly, and monitor more carefully than you would in a dog of equivalent weight.

The Critical Distinction: CBD Overdose Versus THC Toxicosis

This section is the reason this article exists. It is the distinction that most consumer content about pet CBD either does not make or makes imprecisely, and the failure to make it clearly causes owners to either panic unnecessarily when their pet has consumed too much CBD, or to delay seeking care when their pet has actually been exposed to THC. Both errors have consequences.

Binagia, Gregory, and Yankin, publishing in the Journal of the American Veterinary Medical Association in 2024, conducted the largest retrospective study of confirmed marijuana and THC toxicosis in dogs to date, examining 223 cases from January 2017 through July 2021 at Michigan State University and Texas A&M University.^[6] Every dog in the study had either a known history of marijuana ingestion or a positive THC result on a human urine multidrug test. The clinical picture that emerged from those 223 cases is the definitive description of what THC toxicosis looks like in dogs, and it looks nothing like CBD overdose.

Ataxia was present in 197 of 223 dogs, a rate of 88.3 percent. Hyperesthesia was present in 168 of 223, a rate of 75.3 percent. Lethargy and depressed mentation were present in 140 of 223, a rate of 62.8 percent. Urinary incontinence was present in 102 of 223, a rate of 45.7 percent. Trembling and shaking were present in 73 of 223, a rate of 32.7 percent. Tachycardia was present in 82 of 222, a rate of 37 percent. Hyperthermia was present in 48 of 212, a rate of 22.6 percent. Mydriasis was present in 50 of 223, a rate of 22.4 percent. Mild hyperkalemia was documented in 39 of 76 dogs with electrolyte data, a rate of 51.3 percent. Mild ionized hypercalcemia was documented in 53 of 67 dogs, a rate of 79.1 percent. All 223 dogs survived. No treatment was required in 129 of 223 cases, a rate of 57.8 percent.

Marsigliano, Green, and DiGangi, publishing in Frontiers in Veterinary Science in 2024, reported a case series of six dogs with confirmed or presumptive THC toxicosis treated with transmucosal CBD-infused dissolving sheets at doses ranging from 0.4 to 2.6 milligrams per kilogram.^[7] Clinical signs were noticeably reduced in five of six dogs within 45 minutes of CBD administration. Complete resolution was documented in three of six cases within 28 hours. No adverse effects from the CBD administration were reported in any case. The mechanistic explanation offered by the authors is that CBD directly antagonizes the excitatory effects of THC and potentiates its depressant effects via displacement from plasma protein binding sites, with transmucosal delivery bypassing first-pass hepatic metabolism to achieve peak serum concentration within 30 to 60 minutes. The clinical implication is not merely that CBD is safe. It is that CBD, administered correctly, may actively counteract the toxicological effects of THC.

What to Do If You Think Your Pet Had Too Much CBD

The clinical decision framework that emerges from the research is straightforward, and it begins with the same question the data demands: are the signs you are observing consistent with CBD excess, or are they consistent with THC toxicosis? The answer to that question determines everything that follows.

For mild signs consistent with CBD excess, meaning lethargy without neurological involvement, soft stool, reduced appetite, or mild gastrointestinal upset, the appropriate response is supportive care at home. Ensure water is freely accessible. Provide a comfortable, quiet rest area. Monitor the animal's behavior and responsiveness at regular intervals. The pharmacokinetic data from Hammerding and Brutlag confirms an oral CBD elimination half-life of 0.5 to 5.8 hours in dogs and 6.7 to 17.1 hours in cats, meaning the majority of mild signs will resolve within 24 to 48 hours as the cannabinoid clears. No specific antidote is required. No emergency intervention is indicated.

For moderate signs, meaning persistent vomiting that does not resolve within several hours, lethargy that extends beyond 48 hours, or reduced responsiveness that does not improve, veterinarian consultation is appropriate. The treating clinician may recommend antiemetics, gastroprotectants, digestive support, or fluid therapy depending on the clinical picture. Hammerding and Brutlag confirm that activated charcoal is generally not indicated given the safety profile of CBD, and that emesis induction with apomorphine is reserved for massive ingestions in dogs only, never in cats.

For severe neurological signs, the framework collapses to a single instruction: seek emergency veterinary care immediately. Ataxia, tremors, urinary incontinence, hyperesthesia, mydriasis, tachycardia, hyperthermia, or altered mentation after cannabis exposure are the clinical signature of THC toxicosis, not CBD overdose. The Binagia et al. dataset confirms that 57.8 percent of confirmed THC toxicosis cases required no treatment and all 223 dogs survived, but that outcome was achieved under veterinary observation, not at home. The distinction between a dog that will recover without intervention and a dog that requires supportive care is a clinical judgment, not a consumer calculation.

Why Formulation and Extraction Method Determine the Risk Profile

The adverse event data from the Pet Poison Helpline, as analyzed by Hammerding and Brutlag, contains a finding that the cannabinoid industry has a commercial incentive to minimize and a clinical obligation to state plainly: the neurological signs documented in CBD cases are likely attributable to THC contamination, synthetic cannabinoids, or other adulterants in poorly manufactured products, not to CBD itself.^[2] The implication is direct. The risk profile of a CBD product is not determined solely by its CBD content. It is determined by what else is in it, what the extraction process introduced or failed to remove, and whether an independent laboratory with demonstrated technical competence has verified the finished batch against a full-panel specification.

Brown and colleagues, publishing in Veterinary Immunology and Immunopathology in 2023, confirmed that cannabinoid-mediated cytokine suppression in canine immune cells is vehicle-dependent.^[8] The carrier through which cannabinoids reach the receptor is not a secondary consideration. It is a primary determinant of bioavailability, onset, and the concentration at which the active compound reaches target tissue. A solventless extraction process eliminates the possibility of residual solvent contamination in the finished product. An ISO 17025-accredited third-party laboratory provides independent verification that the batch-specific COA reflects the actual composition of the product in the bottle, not the theoretical composition of the formulation on paper.

Dosing: Starting Low and Titrating Up

The clinical studies that produced the safety data in this article used doses that are higher than most pet owners administer in practice. Bookout and colleagues used 5 milligrams per kilogram per day in dogs over 90 days. Coltherd and colleagues used 4 milligrams per kilogram per day in cats over 26 weeks. The osteoarthritis and dermatitis trials reviewed by Ukai, McGrath, and Wakshlag used 2 milligrams per kilogram twice daily in dogs. These are the doses at which the research was conducted, and they represent the upper range of evidence-informed therapeutic dosing, not starting doses for a naive animal.

The appropriate starting point for a dog or cat with no prior cannabinoid exposure is substantially lower, with gradual titration upward over weeks rather than days, monitoring behavior and response at each increment before increasing. The pharmacokinetic data from Lyons and colleagues confirms high intra-individual variability between cats at identical doses, a finding that applies with equal force to dogs and underscores why a dosing protocol that works for one animal in a household may not be appropriate for another of similar weight and breed.

Frequently Asked Questions